BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 17101249)

  • 1. Improved bioavailability of orally administered mifepristone from PLGA nanoparticles.
    He W; Horn SW; Hussain MD
    Int J Pharm; 2007 Apr; 334(1-2):173-8. PubMed ID: 17101249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles.
    Kumar PS; Ramakrishna S; Saini TR; Diwan PV
    Pharmazie; 2006 Jul; 61(7):613-7. PubMed ID: 16889069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.
    Mittal G; Sahana DK; Bhardwaj V; Ravi Kumar MN
    J Control Release; 2007 May; 119(1):77-85. PubMed ID: 17349712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
    Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
    Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis.
    Kumar G; Sharma S; Shafiq N; Pandhi P; Khuller GK; Malhotra S
    Drug Deliv; 2011 Jan; 18(1):65-73. PubMed ID: 20735202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) nanoparticles and its antibacterial activity.
    Jeong YI; Na HS; Seo DH; Kim DG; Lee HC; Jang MK; Na SK; Roh SH; Kim SI; Nah JW
    Int J Pharm; 2008 Mar; 352(1-2):317-23. PubMed ID: 18160236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method.
    Choi SH; Park TG
    Int J Pharm; 2006 Mar; 311(1-2):223-8. PubMed ID: 16423477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content.
    Budhian A; Siegel SJ; Winey KI
    Int J Pharm; 2007 May; 336(2):367-75. PubMed ID: 17207944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin.
    Yin Y; Chen D; Qiao M; Lu Z; Hu H
    J Control Release; 2006 Dec; 116(3):337-45. PubMed ID: 17097180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles.
    Dillen K; Vandervoort J; Van den Mooter G; Ludwig A
    Int J Pharm; 2006 May; 314(1):72-82. PubMed ID: 16600538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indocyanine green-loaded biodegradable nanoparticles: preparation, physicochemical characterization and in vitro release.
    Saxena V; Sadoqi M; Shao J
    Int J Pharm; 2004 Jul; 278(2):293-301. PubMed ID: 15196634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.
    Italia JL; Bhatt DK; Bhardwaj V; Tikoo K; Kumar MN
    J Control Release; 2007 Jun; 119(2):197-206. PubMed ID: 17399839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
    Mundargi RC; Babu VR; Rangaswamy V; Patel P; Aminabhavi TM
    J Control Release; 2008 Feb; 125(3):193-209. PubMed ID: 18083265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PLGA nanoparticles for the oral delivery of 5-Fluorouracil using high pressure homogenization-emulsification as the preparation method and in vitro/in vivo studies.
    Li X; Xu Y; Chen G; Wei P; Ping Q
    Drug Dev Ind Pharm; 2008 Jan; 34(1):107-15. PubMed ID: 18214762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution.
    Mainardes RM; Evangelista RC
    Int J Pharm; 2005 Feb; 290(1-2):137-44. PubMed ID: 15664139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality.
    McCarron PA; Marouf WM; Donnelly RF; Scott C
    J Biomed Mater Res A; 2008 Dec; 87(4):873-84. PubMed ID: 18228271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition.
    Ling G; Zhang P; Zhang W; Sun J; Meng X; Qin Y; Deng Y; He Z
    J Control Release; 2010 Dec; 148(2):241-8. PubMed ID: 20727928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms.
    Xie X; Tao Q; Zou Y; Zhang F; Guo M; Wang Y; Wang H; Zhou Q; Yu S
    J Agric Food Chem; 2011 Sep; 59(17):9280-9. PubMed ID: 21797282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness.
    Ishihara T; Kubota T; Choi T; Takahashi M; Ayano E; Kanazawa H; Higaki M
    Int J Pharm; 2009 Jun; 375(1-2):148-54. PubMed ID: 19481700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro release and stereoselective disposition of flurbiprofen loaded to poly(D,L-lactide- co-glycolide) nanoparticles in rats.
    Radwan MA; Aboul-Enein HY
    Chirality; 2004 Feb; 16(2):119-25. PubMed ID: 14712475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.